KR20230160308A - Vmat2 억제제 및 사용 방법 - Google Patents
Vmat2 억제제 및 사용 방법 Download PDFInfo
- Publication number
- KR20230160308A KR20230160308A KR1020237035676A KR20237035676A KR20230160308A KR 20230160308 A KR20230160308 A KR 20230160308A KR 1020237035676 A KR1020237035676 A KR 1020237035676A KR 20237035676 A KR20237035676 A KR 20237035676A KR 20230160308 A KR20230160308 A KR 20230160308A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- methoxy
- dimethylpropyl
- isoquinolin
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 921
- 238000000034 method Methods 0.000 claims abstract description 122
- 239000000203 mixture Substances 0.000 claims abstract description 122
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 955
- 150000003839 salts Chemical class 0.000 claims description 243
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 168
- 208000035475 disorder Diseases 0.000 claims description 124
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 claims description 89
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 claims description 88
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 83
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 125000001153 fluoro group Chemical group F* 0.000 claims description 61
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 44
- 208000020016 psychiatric disease Diseases 0.000 claims description 44
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 41
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 41
- 230000000926 neurological effect Effects 0.000 claims description 41
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 40
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 39
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 38
- 208000012902 Nervous system disease Diseases 0.000 claims description 36
- 208000025966 Neurological disease Diseases 0.000 claims description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 239000001301 oxygen Substances 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000005842 heteroatom Chemical group 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 125000004043 oxo group Chemical group O=* 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 28
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 229910052717 sulfur Chemical group 0.000 claims description 27
- 239000011593 sulfur Chemical group 0.000 claims description 27
- 229940127557 pharmaceutical product Drugs 0.000 claims description 26
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
- FMPBKSCVKIPVKQ-DJIMGWMZSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@@H]3O FMPBKSCVKIPVKQ-DJIMGWMZSA-N 0.000 claims description 24
- 206010008748 Chorea Diseases 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- 208000000269 Hyperkinesis Diseases 0.000 claims description 23
- 208000012601 choreatic disease Diseases 0.000 claims description 23
- QMXSHMMEEDPFTM-KBAYOESNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@@H]3O QMXSHMMEEDPFTM-KBAYOESNSA-N 0.000 claims description 20
- 208000019022 Mood disease Diseases 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 18
- 208000012661 Dyskinesia Diseases 0.000 claims description 16
- 208000028017 Psychotic disease Diseases 0.000 claims description 16
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 15
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 14
- 208000023105 Huntington disease Diseases 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 208000011117 substance-related disease Diseases 0.000 claims description 14
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 13
- 208000029560 autism spectrum disease Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 208000010118 dystonia Diseases 0.000 claims description 12
- 208000015015 neurological dysfunction Diseases 0.000 claims description 12
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 11
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims description 11
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 11
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims description 10
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 claims description 10
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 10
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 claims description 10
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 10
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 10
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 206010010356 Congenital anomaly Diseases 0.000 claims description 10
- 208000014094 Dystonic disease Diseases 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 10
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 10
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 10
- 206010003591 Ataxia Diseases 0.000 claims description 9
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims description 9
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 claims description 9
- 208000022610 schizoaffective disease Diseases 0.000 claims description 9
- 201000009032 substance abuse Diseases 0.000 claims description 9
- YVEXBAPWAUSOFZ-ATZDWAIDSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1CC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1CC1)[C@@H]3O YVEXBAPWAUSOFZ-ATZDWAIDSA-N 0.000 claims description 8
- BAHYKIGSDBVTRQ-YCEFEEMOSA-N C[C@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O Chemical compound C[C@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O BAHYKIGSDBVTRQ-YCEFEEMOSA-N 0.000 claims description 8
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims description 8
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 claims description 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 claims description 8
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- QYIUGLDNEJATFW-DJIMGWMZSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC)[C@@H]3O QYIUGLDNEJATFW-DJIMGWMZSA-N 0.000 claims description 7
- CKCGBSGKOHQFKB-ATZDWAIDSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1COC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1COC1)[C@@H]3O CKCGBSGKOHQFKB-ATZDWAIDSA-N 0.000 claims description 7
- ROUGUCFWHYJEOY-OYRIPWCXSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@@H](C(F)(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@@H](C(F)(F)F)O)[C@@H]3O ROUGUCFWHYJEOY-OYRIPWCXSA-N 0.000 claims description 7
- SRMWOIMETJOQAR-HNBVOPMISA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O[C@H]1COCC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O[C@H]1COCC1)[C@@H]3O SRMWOIMETJOQAR-HNBVOPMISA-N 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 230000036651 mood Effects 0.000 claims description 7
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 230000009251 neurologic dysfunction Effects 0.000 claims description 7
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 6
- 208000027534 Emotional disease Diseases 0.000 claims description 6
- 206010061296 Motor dysfunction Diseases 0.000 claims description 6
- 208000016285 Movement disease Diseases 0.000 claims description 6
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 208000018300 basal ganglia disease Diseases 0.000 claims description 6
- 230000003542 behavioural effect Effects 0.000 claims description 6
- 208000016097 disease of metabolism Diseases 0.000 claims description 6
- 230000002124 endocrine Effects 0.000 claims description 6
- 208000030172 endocrine system disease Diseases 0.000 claims description 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 6
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 6
- 210000003079 salivary gland Anatomy 0.000 claims description 6
- 231100000736 substance abuse Toxicity 0.000 claims description 6
- 201000006152 substance dependence Diseases 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 claims description 5
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- QYIUGLDNEJATFW-BHYGNILZSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OC)[C@@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OC)[C@@H]3O QYIUGLDNEJATFW-BHYGNILZSA-N 0.000 claims description 5
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 5
- 208000017701 Endocrine disease Diseases 0.000 claims description 5
- 208000030653 Jaw disease Diseases 0.000 claims description 5
- 208000008601 Polycythemia Diseases 0.000 claims description 5
- 208000026375 Salivary gland disease Diseases 0.000 claims description 5
- 210000004227 basal ganglia Anatomy 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 claims description 5
- 230000036244 malformation Effects 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 208000030194 mouth disease Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000001272 neurogenic effect Effects 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 208000019180 nutritional disease Diseases 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
- CXWLMNGPEHRGEC-YMPZKCBVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC=C1)[C@@H]3O CXWLMNGPEHRGEC-YMPZKCBVSA-N 0.000 claims description 4
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 4
- 206010029216 Nervousness Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006289 Rett Syndrome Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- LPIOWWWCBNQGNE-UHFFFAOYSA-N OC1=CC2N(CC1)CCC1=CC=CC=C21 Chemical compound OC1=CC2N(CC1)CCC1=CC=CC=C21 LPIOWWWCBNQGNE-UHFFFAOYSA-N 0.000 claims description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- WZXQPKWPXPAXEJ-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(C)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(C)O)[C@@H]3O WZXQPKWPXPAXEJ-BHIYHBOVSA-N 0.000 claims 6
- DLOKKIOXZYBBJK-KBAYOESNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@@H]3O DLOKKIOXZYBBJK-KBAYOESNSA-N 0.000 claims 6
- PTYLBTJOKCDSAR-DJIMGWMZSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)F)[C@@H]3O PTYLBTJOKCDSAR-DJIMGWMZSA-N 0.000 claims 6
- AHPFMEMYGKLIHB-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC#N)CC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC#N)CC1)[C@@H]3O AHPFMEMYGKLIHB-HMXCVIKNSA-N 0.000 claims 6
- IOZQNRPXHXILJP-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)F)[C@@H]3O IOZQNRPXHXILJP-BHIYHBOVSA-N 0.000 claims 6
- QGDYCYBDMPTGHI-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCC1)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCC1)O)[C@@H]3O QGDYCYBDMPTGHI-MISYRCLQSA-N 0.000 claims 6
- OIGBEYXTTUBXGT-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(COC1)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(COC1)F)[C@@H]3O OIGBEYXTTUBXGT-BHIYHBOVSA-N 0.000 claims 6
- QFZAMTFPZZZDQB-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1COC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1COC1)[C@@H]3O QFZAMTFPZZZDQB-MISYRCLQSA-N 0.000 claims 6
- WLPUPLFEGXATRU-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC1(CC1)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC1(CC1)C#N)[C@@H]3O WLPUPLFEGXATRU-HMXCVIKNSA-N 0.000 claims 6
- NPKKAAMISJSBHM-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC(C)(C)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC(C)(C)C#N)[C@@H]3O NPKKAAMISJSBHM-HMXCVIKNSA-N 0.000 claims 6
- UBKHEVGEYZQERC-ODZZBHCRSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC(C1CC1)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC(C1CC1)C#N)[C@@H]3O UBKHEVGEYZQERC-ODZZBHCRSA-N 0.000 claims 6
- SDCORAARCJJMDQ-CEMLEFRQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC1(CCC1)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC1(CCC1)C#N)[C@@H]3O SDCORAARCJJMDQ-CEMLEFRQSA-N 0.000 claims 6
- ROUGUCFWHYJEOY-WVSUBDOOSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@H](C(F)(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@H](C(F)(F)F)O)[C@@H]3O ROUGUCFWHYJEOY-WVSUBDOOSA-N 0.000 claims 6
- SRMWOIMETJOQAR-PIKOESSRSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O[C@@H]1COCC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O[C@@H]1COCC1)[C@@H]3O SRMWOIMETJOQAR-PIKOESSRSA-N 0.000 claims 6
- HJXRBWQIQIMXEX-KBAYOESNSA-N CCOC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC Chemical compound CCOC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC HJXRBWQIQIMXEX-KBAYOESNSA-N 0.000 claims 6
- QIPVBLUWQJGWFO-KKZITWDXSA-N CC(C(F)(F)F)OC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC Chemical compound CC(C(F)(F)F)OC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC QIPVBLUWQJGWFO-KKZITWDXSA-N 0.000 claims 5
- KCQRHDVSJPUTDH-NSISKUIASA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1CCC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1CCC1)[C@@H]3O KCQRHDVSJPUTDH-NSISKUIASA-N 0.000 claims 5
- DISUBJZEUNNHSO-SUYGWPACSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C(F)F)O)[C@@H]3O DISUBJZEUNNHSO-SUYGWPACSA-N 0.000 claims 4
- JCIHONQJRYFQBH-ALNJEAPDSA-N CC(C#N)OCCOC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC Chemical compound CC(C#N)OCCOC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC JCIHONQJRYFQBH-ALNJEAPDSA-N 0.000 claims 2
- QYIUGLDNEJATFW-XIRDDKMYSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OC)[C@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OC)[C@H]3O QYIUGLDNEJATFW-XIRDDKMYSA-N 0.000 claims 2
- DLOKKIOXZYBBJK-RYQLBKOJSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@@H]3O DLOKKIOXZYBBJK-RYQLBKOJSA-N 0.000 claims 2
- DLOKKIOXZYBBJK-SZMVWBNQSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@H]3O DLOKKIOXZYBBJK-SZMVWBNQSA-N 0.000 claims 2
- FMPBKSCVKIPVKQ-BHYGNILZSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@@H]3O FMPBKSCVKIPVKQ-BHYGNILZSA-N 0.000 claims 2
- FMPBKSCVKIPVKQ-XIRDDKMYSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@H]3O FMPBKSCVKIPVKQ-XIRDDKMYSA-N 0.000 claims 2
- PTYLBTJOKCDSAR-BHYGNILZSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)F)[C@@H]3O PTYLBTJOKCDSAR-BHYGNILZSA-N 0.000 claims 2
- PTYLBTJOKCDSAR-XIRDDKMYSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC(F)F)[C@H]3O PTYLBTJOKCDSAR-XIRDDKMYSA-N 0.000 claims 2
- QMXSHMMEEDPFTM-RYQLBKOJSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@@H]3O QMXSHMMEEDPFTM-RYQLBKOJSA-N 0.000 claims 2
- QMXSHMMEEDPFTM-SZMVWBNQSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@H]3O QMXSHMMEEDPFTM-SZMVWBNQSA-N 0.000 claims 2
- CGBFSSWLLWRHLC-KGYQZRGHSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CC1)CC1(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CC1)CC1(F)F)[C@@H]3O CGBFSSWLLWRHLC-KGYQZRGHSA-N 0.000 claims 2
- DHXMFMDHHDTDQI-TYTBRBHCSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CC1)CCC1C(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CC1)CCC1C(F)(F)F)[C@@H]3O DHXMFMDHHDTDQI-TYTBRBHCSA-N 0.000 claims 2
- KXNMCUDNKTVTBU-DRLCJYQTSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CCC1)C1F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CCC1)C1F)[C@@H]3O KXNMCUDNKTVTBU-DRLCJYQTSA-N 0.000 claims 2
- HBRJCKNTXZLSSK-XFQGIKGNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CCN1CC(F)(F)F)C1=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC(CCN1CC(F)(F)F)C1=O)[C@@H]3O HBRJCKNTXZLSSK-XFQGIKGNSA-N 0.000 claims 2
- QYIUGLDNEJATFW-OIISXLGYSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC)[C@H]3O QYIUGLDNEJATFW-OIISXLGYSA-N 0.000 claims 2
- AWGAREGKLHXKTP-NSISKUIASA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1CN(C)C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC1CN(C)C1)[C@@H]3O AWGAREGKLHXKTP-NSISKUIASA-N 0.000 claims 2
- IUGGGIJXCJCJAL-LHZNIWEOSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(C(F)(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(C(F)(F)F)O)[C@@H]3O IUGGGIJXCJCJAL-LHZNIWEOSA-N 0.000 claims 2
- DLOKKIOXZYBBJK-NXHRZFHOSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)(F)F)[C@H]3O DLOKKIOXZYBBJK-NXHRZFHOSA-N 0.000 claims 2
- YLFWCHWJTATCGB-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)=C)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C)=C)[C@@H]3O YLFWCHWJTATCGB-MISYRCLQSA-N 0.000 claims 2
- YTBYAYAJXQNECF-XJNYQNQMSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C1)(C2)CC12F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C1)(C2)CC12F)[C@@H]3O YTBYAYAJXQNECF-XJNYQNQMSA-N 0.000 claims 2
- LDFMCFCWODIMPD-DSSQQLCSSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C1)C1(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C1)C1(F)F)[C@@H]3O LDFMCFCWODIMPD-DSSQQLCSSA-N 0.000 claims 2
- LXSUAOKNXNJXMJ-BDHQVWGLSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C1)CC1(C(F)(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C1)CC1(C(F)(F)F)O)[C@@H]3O LXSUAOKNXNJXMJ-BDHQVWGLSA-N 0.000 claims 2
- HKNGWGDXOMOCKC-UEVCKROQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C=C1)=CC=C1F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C=C1)=CC=C1F)[C@@H]3O HKNGWGDXOMOCKC-UEVCKROQSA-N 0.000 claims 2
- SZTXFMKBTCHNRX-UEVCKROQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C=C1)=CC=C1S(C(F)F)(=O)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(C=C1)=CC=C1S(C(F)F)(=O)=O)[C@@H]3O SZTXFMKBTCHNRX-UEVCKROQSA-N 0.000 claims 2
- DYKSSCNOKRZNIW-DSSQQLCSSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC(F)(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC(F)(F)F)O)[C@@H]3O DYKSSCNOKRZNIW-DSSQQLCSSA-N 0.000 claims 2
- YHMDDMOQVGRBPC-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC1)(CCC1(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC1)(CCC1(F)F)O)[C@@H]3O YHMDDMOQVGRBPC-HMXCVIKNSA-N 0.000 claims 2
- BADAJMPTNVXHLW-YMPZKCBVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC1)CCN1C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC1)CCN1C#N)[C@@H]3O BADAJMPTNVXHLW-YMPZKCBVSA-N 0.000 claims 2
- LESBAEMIZGXZNK-CEMLEFRQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC1)CCS1(=O)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CC1)CCS1(=O)=O)[C@@H]3O LESBAEMIZGXZNK-CEMLEFRQSA-N 0.000 claims 2
- MKDVABNGUFQBMP-FQMOWQLGSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CN1CCOCC1)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(CN1CCOCC1)O)[C@@H]3O MKDVABNGUFQBMP-FQMOWQLGSA-N 0.000 claims 2
- OVZARBMCCOEVQP-KGYQZRGHSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(COCC(F)(F)F)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(COCC(F)(F)F)O)[C@@H]3O OVZARBMCCOEVQP-KGYQZRGHSA-N 0.000 claims 2
- DJSSYSRTCGPUNH-DJIMGWMZSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)(F)Cl)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)(F)Cl)[C@@H]3O DJSSYSRTCGPUNH-DJIMGWMZSA-N 0.000 claims 2
- FMPBKSCVKIPVKQ-OIISXLGYSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)(F)F)[C@H]3O FMPBKSCVKIPVKQ-OIISXLGYSA-N 0.000 claims 2
- PTYLBTJOKCDSAR-OIISXLGYSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(F)F)[C@H]3O PTYLBTJOKCDSAR-OIISXLGYSA-N 0.000 claims 2
- PXVFXCBUSIOJET-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(N(C)C)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(N(C)C)=O)[C@@H]3O PXVFXCBUSIOJET-BHIYHBOVSA-N 0.000 claims 2
- QSSZFEDMSWHPPT-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(N(C)CC(F)(F)F)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(N(C)CC(F)(F)F)=O)[C@@H]3O QSSZFEDMSWHPPT-BHIYHBOVSA-N 0.000 claims 2
- RRBCXLGMWDTEJX-UEVCKROQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(N=C1)=CC=C1C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(N=C1)=CC=C1C#N)[C@@H]3O RRBCXLGMWDTEJX-UEVCKROQSA-N 0.000 claims 2
- FQFJWLIFKZHLHS-KBAYOESNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(NC)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC(NC)=O)[C@@H]3O FQFJWLIFKZHLHS-KBAYOESNSA-N 0.000 claims 2
- ANHZKFSHJJZDIF-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)C#N)[C@@H]3O ANHZKFSHJJZDIF-MISYRCLQSA-N 0.000 claims 2
- ZKRQCJVFLOQPTP-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)C(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)C(F)F)[C@@H]3O ZKRQCJVFLOQPTP-BHIYHBOVSA-N 0.000 claims 2
- IOZQNRPXHXILJP-QRQLOZEOSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)F)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)F)[C@H]3O IOZQNRPXHXILJP-QRQLOZEOSA-N 0.000 claims 2
- LCIWQKGNSKAULH-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)OS(C)(=O)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)OS(C)(=O)=O)[C@@H]3O LCIWQKGNSKAULH-MISYRCLQSA-N 0.000 claims 2
- PAUUCMXOQHARIE-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)S(C)(=O)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CC1)S(C)(=O)=O)[C@@H]3O PAUUCMXOQHARIE-MISYRCLQSA-N 0.000 claims 2
- LXPUYKBHOBPKOL-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCC1)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCC1)C#N)[C@@H]3O LXPUYKBHOBPKOL-HMXCVIKNSA-N 0.000 claims 2
- KHMAOASQYXNVBZ-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCC1)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCC1)F)[C@@H]3O KHMAOASQYXNVBZ-MISYRCLQSA-N 0.000 claims 2
- OOXIUTGNNHJJBY-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCCC1)C(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(CCCC1)C(F)(F)F)[C@@H]3O OOXIUTGNNHJJBY-HMXCVIKNSA-N 0.000 claims 2
- NJLPGJMSYQWRSV-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(COCCOC1)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1(COCCOC1)F)[C@@H]3O NJLPGJMSYQWRSV-HMXCVIKNSA-N 0.000 claims 2
- FDAIRLMTEQXHBE-UEVCKROQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC(F)=CC=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC(F)=CC=C1)[C@@H]3O FDAIRLMTEQXHBE-UEVCKROQSA-N 0.000 claims 2
- UZPGODFYYNIADZ-ZPMCFJSWSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=C(C#N)O1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=C(C#N)O1)[C@@H]3O UZPGODFYYNIADZ-ZPMCFJSWSA-N 0.000 claims 2
- OQDBZFWTZXTWCI-UEVCKROQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=C(C(F)(F)F)C=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=C(C(F)(F)F)C=C1)[C@@H]3O OQDBZFWTZXTWCI-UEVCKROQSA-N 0.000 claims 2
- KQUKSNCEVQEBMZ-GMKZXUHWSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC(C#N)=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC(C#N)=C1)[C@@H]3O KQUKSNCEVQEBMZ-GMKZXUHWSA-N 0.000 claims 2
- AEORDBJAZZHNJG-SXSPYAJSSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC(C#N)=N1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC(C#N)=N1)[C@@H]3O AEORDBJAZZHNJG-SXSPYAJSSA-N 0.000 claims 2
- IFOPVMQJZDRXRH-NSISKUIASA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=NO1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=NO1)[C@@H]3O IFOPVMQJZDRXRH-NSISKUIASA-N 0.000 claims 2
- JKTVZHZYQVLREV-NSISKUIASA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=COC=N1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=COC=N1)[C@@H]3O JKTVZHZYQVLREV-NSISKUIASA-N 0.000 claims 2
- HLDNBQCSOMGYNL-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=C(C)O1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=C(C)O1)[C@@H]3O HLDNBQCSOMGYNL-MISYRCLQSA-N 0.000 claims 2
- SIQNENCYBGENLT-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=CC=N1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=CC=N1)[C@@H]3O SIQNENCYBGENLT-MISYRCLQSA-N 0.000 claims 2
- VPUJMCNZDVLNIW-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=CN1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=CN1)[C@@H]3O VPUJMCNZDVLNIW-BHIYHBOVSA-N 0.000 claims 2
- HRKBOMRVJRRWBH-KBAYOESNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=NO1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NC=NO1)[C@@H]3O HRKBOMRVJRRWBH-KBAYOESNSA-N 0.000 claims 2
- XKVMOGFTMKLBOC-NSISKUIASA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NOC=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=NOC=C1)[C@@H]3O XKVMOGFTMKLBOC-NSISKUIASA-N 0.000 claims 2
- YXJANYONOKAOQW-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1CC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1CC1)[C@@H]3O YXJANYONOKAOQW-MISYRCLQSA-N 0.000 claims 2
- KISWGZHYTDIEPH-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1CCC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1CCC1)[C@@H]3O KISWGZHYTDIEPH-HMXCVIKNSA-N 0.000 claims 2
- PRFCERVTROWVGU-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1CN(C)C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1CN(C)C1)[C@@H]3O PRFCERVTROWVGU-HMXCVIKNSA-N 0.000 claims 2
- OYYJYYIGHWPBTC-AGILITTLSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(C=C1)=CC=C1F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(C=C1)=CC=C1F)[C@@H]3O OYYJYYIGHWPBTC-AGILITTLSA-N 0.000 claims 2
- COPUTSZYYODZSE-KBAYOESNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(F)(F)Cl)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(F)(F)Cl)[C@@H]3O COPUTSZYYODZSE-KBAYOESNSA-N 0.000 claims 2
- QMXSHMMEEDPFTM-NXHRZFHOSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC(F)(F)F)[C@H]3O QMXSHMMEEDPFTM-NXHRZFHOSA-N 0.000 claims 2
- KSMZZAACAYZTBO-AGILITTLSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC1=CC=C(C(F)(F)F)C=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCC1=CC=C(C(F)(F)F)C=C1)[C@@H]3O KSMZZAACAYZTBO-AGILITTLSA-N 0.000 claims 2
- TYTXWQXTCRDMJK-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCCC(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCCC(F)(F)F)[C@@H]3O TYTXWQXTCRDMJK-BHIYHBOVSA-N 0.000 claims 2
- ZCCWRBHTZCUKQQ-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCCCC(F)(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCCCC(F)(F)F)[C@@H]3O ZCCWRBHTZCUKQQ-MISYRCLQSA-N 0.000 claims 2
- CBJFUYVGSKDRKG-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCCS(C)(=O)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCCS(C)(=O)=O)[C@@H]3O CBJFUYVGSKDRKG-MISYRCLQSA-N 0.000 claims 2
- RUMVGBMUKSJUBV-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCN(CC1)CC1(F)F)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCN(CC1)CC1(F)F)[C@@H]3O RUMVGBMUKSJUBV-HMXCVIKNSA-N 0.000 claims 2
- NJPHMHYESCLZJV-HMXCVIKNSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCN1C=NC=C1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCN1C=NC=C1)[C@@H]3O NJPHMHYESCLZJV-HMXCVIKNSA-N 0.000 claims 2
- GTLHIDZBWBDCNY-YMPZKCBVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC1(CCOCC1)C#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC1(CCOCC1)C#N)[C@@H]3O GTLHIDZBWBDCNY-YMPZKCBVSA-N 0.000 claims 2
- NKXOBAUJSRSBAZ-DUXKGJEZSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC1COC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOC1COC1)[C@@H]3O NKXOBAUJSRSBAZ-DUXKGJEZSA-N 0.000 claims 2
- VNVDAEBFOGGNEK-MISYRCLQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOCC#N)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCCOCC#N)[C@@H]3O VNVDAEBFOGGNEK-MISYRCLQSA-N 0.000 claims 2
- KCHMCJRTQLKKHR-BHIYHBOVSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCS(N(C)C)(=O)=O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCS(N(C)C)(=O)=O)[C@@H]3O KCHMCJRTQLKKHR-BHIYHBOVSA-N 0.000 claims 2
- QPZXDVFKXRGBDU-PSBWJHGTSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@@H](CO)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@@H](CO)O)[C@@H]3O QPZXDVFKXRGBDU-PSBWJHGTSA-N 0.000 claims 2
- CJVDFOMIDVHNEL-HNBVOPMISA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@@H](COC)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@@H](COC)O)[C@@H]3O CJVDFOMIDVHNEL-HNBVOPMISA-N 0.000 claims 2
- CJVDFOMIDVHNEL-PIKOESSRSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@H](COC)O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@H](COC)O)[C@@H]3O CJVDFOMIDVHNEL-PIKOESSRSA-N 0.000 claims 2
- WHNVUGHDIKTQMC-PIKOESSRSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@H]1OCC1)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OC[C@H]1OCC1)[C@@H]3O WHNVUGHDIKTQMC-PIKOESSRSA-N 0.000 claims 2
- GTPWCOXTEVKLNE-HMXCVIKNSA-N CCC(CC)(COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O Chemical compound CCC(CC)(COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O GTPWCOXTEVKLNE-HMXCVIKNSA-N 0.000 claims 2
- DFSLQRIOFWNOFE-PIKOESSRSA-N CC[C@@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O Chemical compound CC[C@@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O DFSLQRIOFWNOFE-PIKOESSRSA-N 0.000 claims 2
- DFSLQRIOFWNOFE-HNBVOPMISA-N CC[C@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O Chemical compound CC[C@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O DFSLQRIOFWNOFE-HNBVOPMISA-N 0.000 claims 2
- FHEKPFIXIQIHGZ-YICCBXQDSA-N CC[C@H]1[C@H](COC(C=C(CCN(C[C@H]2CC(C)(C)C)[C@@H]3C[C@H]2O)C3=C2)=C2OC)C1 Chemical compound CC[C@H]1[C@H](COC(C=C(CCN(C[C@H]2CC(C)(C)C)[C@@H]3C[C@H]2O)C3=C2)=C2OC)C1 FHEKPFIXIQIHGZ-YICCBXQDSA-N 0.000 claims 2
- BAHYKIGSDBVTRQ-RGIVZKHGSA-N C[C@@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O Chemical compound C[C@@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)O BAHYKIGSDBVTRQ-RGIVZKHGSA-N 0.000 claims 2
- CYPTZQNBVUPYPI-JQERWDHBSA-N C[C@@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)OC Chemical compound C[C@@H](COC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC)OC CYPTZQNBVUPYPI-JQERWDHBSA-N 0.000 claims 2
- HJXRBWQIQIMXEX-WNWGNMGJSA-N [2H]C([2H])([2H])C([2H])([2H])OC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC Chemical compound [2H]C([2H])([2H])C([2H])([2H])OC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC HJXRBWQIQIMXEX-WNWGNMGJSA-N 0.000 claims 2
- QYIUGLDNEJATFW-GDIDIGHKSA-N [2H]C([2H])([2H])OC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC Chemical compound [2H]C([2H])([2H])OC(C=C(CCN(C[C@H]1CC(C)(C)C)[C@@H]2C[C@H]1O)C2=C1)=C1OC QYIUGLDNEJATFW-GDIDIGHKSA-N 0.000 claims 2
- 239000010977 jade Substances 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000019000 fluorine Nutrition 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 55
- BIEOFPRQYUUAQI-UHFFFAOYSA-N C12CC(O)C(CC(C)(C)C)CN2CCC2=C1C=C(OC)C(O)=C2 Chemical compound C12CC(O)C(CC(C)(C)C)CN2CCC2=C1C=C(OC)C(O)=C2 BIEOFPRQYUUAQI-UHFFFAOYSA-N 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- 239000007787 solid Substances 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- 230000000155 isotopic effect Effects 0.000 description 39
- 239000000243 solution Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- INAJHVBQYDOUBP-UHFFFAOYSA-N CC(C)(C)CC(CN(CCC1=C2)C(C3)C1=CC(OC)=C2O)C3=O Chemical compound CC(C)(C)CC(CN(CCC1=C2)C(C3)C1=CC(OC)=C2O)C3=O INAJHVBQYDOUBP-UHFFFAOYSA-N 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- 125000004429 atom Chemical group 0.000 description 27
- 239000000843 powder Substances 0.000 description 26
- 239000000126 substance Substances 0.000 description 25
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 24
- 229910052805 deuterium Inorganic materials 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- 238000009826 distribution Methods 0.000 description 21
- MLAYZCMWRNQKQX-UHFFFAOYSA-N 2-hydroxy-1h-isoquinoline Chemical compound C1=CC=C2C=CN(O)CC2=C1 MLAYZCMWRNQKQX-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000013078 crystal Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 229910052729 chemical element Inorganic materials 0.000 description 18
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- 125000004122 cyclic group Chemical group 0.000 description 17
- 239000008186 active pharmaceutical agent Substances 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 229940088679 drug related substance Drugs 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- CXWLMNGPEHRGEC-UHFFFAOYSA-N CC(C)(C)CC(CN(CCC1=C2)C(C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3O Chemical compound CC(C)(C)CC(CN(CCC1=C2)C(C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3O CXWLMNGPEHRGEC-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000010348 incorporation Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- 230000035939 shock Effects 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 208000011580 syndromic disease Diseases 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 12
- 230000001143 conditioned effect Effects 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 125000001188 haloalkyl group Chemical group 0.000 description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 238000004808 supercritical fluid chromatography Methods 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000012279 sodium borohydride Substances 0.000 description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000561 anti-psychotic effect Effects 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 239000003638 chemical reducing agent Substances 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 229910052722 tritium Inorganic materials 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 6
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 6
- 206010001497 Agitation Diseases 0.000 description 6
- 101150065749 Churc1 gene Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 102100038239 Protein Churchill Human genes 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 description 5
- INAJHVBQYDOUBP-UKRRQHHQSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O)C3=O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O)C3=O INAJHVBQYDOUBP-UKRRQHHQSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 208000028683 bipolar I disease Diseases 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 150000005829 chemical entities Chemical class 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229910052738 indium Inorganic materials 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 125000002098 pyridazinyl group Chemical group 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- 238000003828 vacuum filtration Methods 0.000 description 5
- 208000020925 Bipolar disease Diseases 0.000 description 4
- BIEOFPRQYUUAQI-FVQBIDKESA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O)[C@@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O)[C@@H]3O BIEOFPRQYUUAQI-FVQBIDKESA-N 0.000 description 4
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 4
- 208000002033 Myoclonus Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 4
- 101150012828 UPC2 gene Proteins 0.000 description 4
- 238000011360 adjunctive therapy Methods 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 150000004678 hydrides Chemical class 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 235000009518 sodium iodide Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 3
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- KUDXQUUEFIUNBX-UHFFFAOYSA-N CC(C)(C)CC(CN(CCC1=C2)C(C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3=O Chemical compound CC(C)(C)CC(CN(CCC1=C2)C(C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3=O KUDXQUUEFIUNBX-UHFFFAOYSA-N 0.000 description 3
- INAJHVBQYDOUBP-ZFWWWQNUSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2O)C3=O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2O)C3=O INAJHVBQYDOUBP-ZFWWWQNUSA-N 0.000 description 3
- BIEOFPRQYUUAQI-BMFZPTHFSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O)[C@H]3O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2O)[C@H]3O BIEOFPRQYUUAQI-BMFZPTHFSA-N 0.000 description 3
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 3
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 206010063006 Facial spasm Diseases 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 3
- 208000004095 Hemifacial Spasm Diseases 0.000 description 3
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 208000005793 Restless legs syndrome Diseases 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 3
- 208000016620 Tourette disease Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 125000004069 aziridinyl group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- 230000003483 hypokinetic effect Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 3
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 atom Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 description 3
- QVGXLLKOCUKJST-NJFSPNSNSA-N oxygen-18 atom Chemical compound [18O] QVGXLLKOCUKJST-NJFSPNSNSA-N 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 description 3
- 208000016686 tic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- AQZRARFZZMGLHL-REOHCLBHSA-N (2s)-2-(trifluoromethyl)oxirane Chemical compound FC(F)(F)[C@@H]1CO1 AQZRARFZZMGLHL-REOHCLBHSA-N 0.000 description 2
- XYALYQZFDHDDEI-GDBMZVCRSA-N (3R,11bR)-3-(2,2-dimethylpropyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound COc1cc2CCN3C[C@@H](CC(C)(C)C)C(=O)C[C@@H]3c2cc1OC XYALYQZFDHDDEI-GDBMZVCRSA-N 0.000 description 2
- PFCXSNACHOIUGM-UHFFFAOYSA-N 1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CC2=CC=CC=C2C2N1CCC(=O)C2 PFCXSNACHOIUGM-UHFFFAOYSA-N 0.000 description 2
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 2
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 2
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 2
- CMERUCKCPIMRAF-UHFFFAOYSA-N 1,4-diazabicyclo[3.1.1]heptane Chemical compound C1N2CC1NCC2 CMERUCKCPIMRAF-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 2
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 description 2
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- 206010001540 Akathisia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010058504 Ballismus Diseases 0.000 description 2
- 206010004153 Basal ganglion degeneration Diseases 0.000 description 2
- WKBOTKDWSSQWDR-AHCXROLUSA-N Bromine-79 Chemical compound [76Br] WKBOTKDWSSQWDR-AHCXROLUSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- BIEOFPRQYUUAQI-CWRNSKLLSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2O)[C@@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2O)[C@@H]3O BIEOFPRQYUUAQI-CWRNSKLLSA-N 0.000 description 2
- BIEOFPRQYUUAQI-BPUTZDHNSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2O)[C@H]3O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2O)[C@H]3O BIEOFPRQYUUAQI-BPUTZDHNSA-N 0.000 description 2
- KUDXQUUEFIUNBX-IFMALSPDSA-N CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3=O Chemical compound CC(C)(C)C[C@H](CN(CCC1=C2)[C@H](C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3=O KUDXQUUEFIUNBX-IFMALSPDSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- 206010010219 Compulsions Diseases 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 206010020651 Hyperkinesia Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- OBYDREYTQRTLPS-UHFFFAOYSA-N OC1=CC2N(CCC3=C2C=CC=C3)C=C1 Chemical compound OC1=CC2N(CCC3=C2C=CC=C3)C=C1 OBYDREYTQRTLPS-UHFFFAOYSA-N 0.000 description 2
- CFBSTALLQKRQKO-UHFFFAOYSA-N OC1=CCN2CCC3=C(C=CC=C3)C2C1 Chemical compound OC1=CCN2CCC3=C(C=CC=C3)C2C1 CFBSTALLQKRQKO-UHFFFAOYSA-N 0.000 description 2
- 206010029897 Obsessive thoughts Diseases 0.000 description 2
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 2
- OAICVXFJPJFONN-NJFSPNSNSA-N Phosphorus-33 Chemical compound [33P] OAICVXFJPJFONN-NJFSPNSNSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- NINIDFKCEFEMDL-NJFSPNSNSA-N Sulfur-34 Chemical compound [34S] NINIDFKCEFEMDL-NJFSPNSNSA-N 0.000 description 2
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 2
- NINIDFKCEFEMDL-RNFDNDRNSA-N Sulfur-36 Chemical compound [36S] NINIDFKCEFEMDL-RNFDNDRNSA-N 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- FLLNLJJKHKZKMB-UHFFFAOYSA-N boron;tetramethylazanium Chemical compound [B].C[N+](C)(C)C FLLNLJJKHKZKMB-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- CPELXLSAUQHCOX-OUBTZVSYSA-N bromine-81 Chemical compound [81BrH] CPELXLSAUQHCOX-OUBTZVSYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- VEXZGXHMUGYJMC-IGMARMGPSA-N chlorine-35 Chemical compound [35ClH] VEXZGXHMUGYJMC-IGMARMGPSA-N 0.000 description 2
- ZAMOUSCENKQFHK-OUBTZVSYSA-N chlorine-36 Chemical compound [36Cl] ZAMOUSCENKQFHK-OUBTZVSYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013932 dyslexia Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 2
- 238000010575 fractional recrystallization Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000004083 gastrointestinal agent Substances 0.000 description 2
- 229940127227 gastrointestinal drug Drugs 0.000 description 2
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 125000003971 isoxazolinyl group Chemical group 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000005968 oxazolinyl group Chemical group 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229940097886 phosphorus 32 Drugs 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- NINIDFKCEFEMDL-IGMARMGPSA-N sulfur-32 atom Chemical compound [32S] NINIDFKCEFEMDL-IGMARMGPSA-N 0.000 description 2
- NINIDFKCEFEMDL-OUBTZVSYSA-N sulfur-33 atom Chemical compound [33S] NINIDFKCEFEMDL-OUBTZVSYSA-N 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- XYALYQZFDHDDEI-HOCLYGCPSA-N (3S,11bS)-3-(2,2-dimethylpropyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound [H][C@@]12CC(=O)[C@@H](CC(C)(C)C)CN1CCC1=CC(OC)=C(OC)C=C21 XYALYQZFDHDDEI-HOCLYGCPSA-N 0.000 description 1
- BKIQORJIKOPRCG-BYPYZUCNSA-N (3s)-3-iodooxolane Chemical compound I[C@H]1CCOC1 BKIQORJIKOPRCG-BYPYZUCNSA-N 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
- 125000005904 1,2,3,4-tetrahydro-1,6-naphthyridinyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- LFHLEABTNIQIQO-UHFFFAOYSA-N 1H-isoindole Chemical compound C1=CC=C2CN=CC2=C1 LFHLEABTNIQIQO-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- SZTIZZFKWQWSSP-UHFFFAOYSA-N 3-bromooxetane Chemical compound BrC1COC1 SZTIZZFKWQWSSP-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- HJGMGFYESSOUMR-UHFFFAOYSA-N 7-methoxy-3,4-dihydroisoquinolin-6-ol Chemical compound C1=NCCC2=C1C=C(OC)C(O)=C2 HJGMGFYESSOUMR-UHFFFAOYSA-N 0.000 description 1
- ZIRDRQBTZSUXQD-UHFFFAOYSA-N 7-methoxy-6-phenylmethoxy-3,4-dihydroisoquinoline Chemical compound COC1=CC=2C=NCCC=2C=C1OCC1=CC=CC=C1 ZIRDRQBTZSUXQD-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010070883 Alien limb syndrome Diseases 0.000 description 1
- 208000005875 Alternating hemiplegia of childhood Diseases 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 206010054895 Baltic myoclonic epilepsy Diseases 0.000 description 1
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 1
- 206010067866 Benign familial neonatal convulsions Diseases 0.000 description 1
- 208000035183 Benign hereditary chorea Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-OIOBTWANSA-N Bromine-77 Chemical compound [77Br] WKBOTKDWSSQWDR-OIOBTWANSA-N 0.000 description 1
- 206010068065 Burning mouth syndrome Diseases 0.000 description 1
- ZHSFGTGZEWDBCZ-UHFFFAOYSA-N CC(C)(C)CC(CN(C)C)C(C)=O Chemical compound CC(C)(C)CC(CN(C)C)C(C)=O ZHSFGTGZEWDBCZ-UHFFFAOYSA-N 0.000 description 1
- KUDXQUUEFIUNBX-UNMCSNQZSA-N CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3=O Chemical compound CC(C)(C)C[C@@H](CN(CCC1=C2)[C@@H](C3)C1=CC(OC)=C2OCC1=CC=CC=C1)C3=O KUDXQUUEFIUNBX-UNMCSNQZSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 208000023169 Congenital Horner syndrome Diseases 0.000 description 1
- 208000006354 Congenital Nystagmus Diseases 0.000 description 1
- 206010049449 Congenital facial nerve hypoplasia Diseases 0.000 description 1
- 206010010474 Congenital flaccid paralysis Diseases 0.000 description 1
- 206010071359 Congenital hemiparesis Diseases 0.000 description 1
- 208000026393 Congenital neurological disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010066088 Fine motor delay Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 206010069118 Gross motor delay Diseases 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000025818 Hereditary motor neurone disease Diseases 0.000 description 1
- 101000641239 Homo sapiens Synaptic vesicular amine transporter Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000020898 Meige disease Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010071034 Microsomia Diseases 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010072941 Olfactory nerve agenesis Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010021592 Pantothenate kinase Proteins 0.000 description 1
- 102100024122 Pantothenate kinase 1 Human genes 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010070912 Pharyngeal dyskinesia Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000014370 Psychogenic movement disease Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010068395 Rabbit syndrome Diseases 0.000 description 1
- 206010057570 Respiratory dyskinesia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 208000007302 Sleep Bruxism Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 208000024453 abnormal involuntary movement Diseases 0.000 description 1
- CPELXLSAUQHCOX-AHCXROLUSA-N ac1l4zwb Chemical compound [76BrH] CPELXLSAUQHCOX-AHCXROLUSA-N 0.000 description 1
- 208000011152 acquired idiopathic torsion dystonia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000005282 allenyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 1
- 201000010295 benign neonatal seizures Diseases 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- NQZKZGHOYUYCHU-UHFFFAOYSA-N boron;tetraethylazanium Chemical compound [B].CC[N+](CC)(CC)CC NQZKZGHOYUYCHU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-FTXFMUIASA-N bromine-75 Chemical compound [75BrH] CPELXLSAUQHCOX-FTXFMUIASA-N 0.000 description 1
- CPELXLSAUQHCOX-NJFSPNSNSA-N bromine-82 Chemical compound [82BrH] CPELXLSAUQHCOX-NJFSPNSNSA-N 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003591 cerebellar nuclei Anatomy 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- UFMOZPONIZKFGT-UHFFFAOYSA-N copper(1+);triphenylphosphane Chemical compound [Cu+].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UFMOZPONIZKFGT-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000005937 cranial nerve palsy Diseases 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HPINOIDASKKAQT-UHFFFAOYSA-N cyclopropyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1CC1 HPINOIDASKKAQT-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 1
- OCXGTPDKNBIOTF-UHFFFAOYSA-N dibromo(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 OCXGTPDKNBIOTF-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 1
- 206010016208 familial periodic paralysis Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002112 hereditary lymphedema II Diseases 0.000 description 1
- 208000030534 hereditary motor neuron disease Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000045572 human SLC18A2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000002161 hypolocomotive effect Effects 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000013339 in-process testing Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000015046 intermittent explosive disease Diseases 0.000 description 1
- XMBWDFGMSWQBCA-CONNIKPHSA-N iodane Chemical compound [135IH] XMBWDFGMSWQBCA-CONNIKPHSA-N 0.000 description 1
- XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical compound [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-NJFSPNSNSA-N iodine-129 atom Chemical compound [129I] ZCYVEMRRCGMTRW-NJFSPNSNSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- HTCGTPMYJVLOJV-UHFFFAOYSA-N lithium;(2-methylpropan-2-yl)oxy-bis(2-methylpropyl)aluminum(1-) Chemical compound [Li+].CC(C)(C)[O-].CC(C)C[Al]CC(C)C HTCGTPMYJVLOJV-UHFFFAOYSA-N 0.000 description 1
- BYSWLWJOROIDHP-UHFFFAOYSA-N lithium;tris(3-ethylpentan-3-yloxy)alumane Chemical compound [Li].CCC(CC)(CC)O[Al](OC(CC)(CC)CC)OC(CC)(CC)CC BYSWLWJOROIDHP-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 208000035520 lymphatic malformation 5 Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000029790 metamphetamine dependence Diseases 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000007576 microinfarct Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000008111 motor development Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000007597 neurodegeneration with brain iron accumulation 3 Diseases 0.000 description 1
- 208000007109 neuroferritinopathy Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000002851 oromandibular dystonia Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000013623 stereotypic movement disease Diseases 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-LZFNBGRKSA-N sulfur-38 atom Chemical compound [38S] NINIDFKCEFEMDL-LZFNBGRKSA-N 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000018724 torsion dystonia Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- CURCMGVZNYCRNY-UHFFFAOYSA-N trimethylazanium;iodide Chemical compound I.CN(C)C CURCMGVZNYCRNY-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164135P | 2021-03-22 | 2021-03-22 | |
| US63/164,135 | 2021-03-22 | ||
| PCT/US2022/021080 WO2022203984A1 (en) | 2021-03-22 | 2022-03-21 | Vmat2 inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230160308A true KR20230160308A (ko) | 2023-11-23 |
Family
ID=81325053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035676A Pending KR20230160308A (ko) | 2021-03-22 | 2022-03-21 | Vmat2 억제제 및 사용 방법 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11718618B2 (https=) |
| EP (2) | EP4606429A3 (https=) |
| JP (1) | JP2024511053A (https=) |
| KR (1) | KR20230160308A (https=) |
| CN (1) | CN117062815A (https=) |
| AR (1) | AR125188A1 (https=) |
| AU (1) | AU2022241988A1 (https=) |
| BR (1) | BR112023016273A2 (https=) |
| CA (1) | CA3207452A1 (https=) |
| CL (1) | CL2023002785A1 (https=) |
| CO (1) | CO2023012322A2 (https=) |
| CR (1) | CR20230448A (https=) |
| DK (1) | DK4168409T3 (https=) |
| DO (1) | DOP2023000197A (https=) |
| EC (1) | ECSP23070370A (https=) |
| ES (1) | ES3032498T3 (https=) |
| FI (1) | FI4168409T3 (https=) |
| HR (1) | HRP20250868T1 (https=) |
| HU (1) | HUE072220T2 (https=) |
| IL (1) | IL305054A (https=) |
| JO (1) | JOP20230205A1 (https=) |
| LT (1) | LT4168409T (https=) |
| MA (1) | MA60072B1 (https=) |
| MD (1) | MD4168409T2 (https=) |
| MX (1) | MX2023010566A (https=) |
| PE (1) | PE20240822A1 (https=) |
| PL (1) | PL4168409T3 (https=) |
| PT (1) | PT4168409T (https=) |
| RS (1) | RS67052B1 (https=) |
| SI (1) | SI4168409T1 (https=) |
| SM (1) | SMT202500408T1 (https=) |
| TW (1) | TW202304901A (https=) |
| WO (1) | WO2022203984A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3209005A (en) | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| CA2650904C (en) | 2006-05-02 | 2015-07-07 | The Trustees Of The University Of Pennsylvania | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US7897769B2 (en) | 2007-10-25 | 2011-03-01 | General Electric Company | Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes |
| US7910738B2 (en) | 2007-11-29 | 2011-03-22 | General Electric Company | Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| US7902364B2 (en) | 2007-11-29 | 2011-03-08 | General Electric Company | Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| US8053578B2 (en) * | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| US8013161B1 (en) | 2007-12-07 | 2011-09-06 | General Electric Company | Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes |
| US7919622B2 (en) | 2007-12-07 | 2011-04-05 | Kande Kankanamalage Dayarathna Amarasinghe | Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| CA2972242A1 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3351247A1 (en) | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| PT2836241T (pt) | 2012-04-10 | 2019-05-30 | Lantheus Medical Imaging Inc | Métodos de síntese de radiofármacos |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US8946255B2 (en) | 2012-12-28 | 2015-02-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
| JP2016506957A (ja) | 2013-01-31 | 2016-03-07 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｖｍａｔ２のベンゾキノロン阻害剤 |
| US20160031840A1 (en) | 2013-03-15 | 2016-02-04 | University Of Kentucky Research Foundation | 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds |
| GB201313291D0 (en) | 2013-07-25 | 2013-09-11 | Ge Healthcare Ltd | Imaging neurological disease |
| WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3398602A1 (en) | 2014-01-27 | 2018-11-07 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9714246B2 (en) | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| RS61645B1 (sr) * | 2015-10-30 | 2021-04-29 | Neurocrine Biosciences Inc | Valbenazin ditozilat i njihovi polimorfi |
| JP6869988B2 (ja) | 2015-12-23 | 2021-05-12 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法 |
| US11999676B2 (en) | 2016-04-21 | 2024-06-04 | University Of Kentucky Research Foundation | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse |
| US10668030B2 (en) | 2016-04-21 | 2020-06-02 | University Of Kentucky Research Foundation | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| TW201906818A (zh) | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| SG11202004165UA (en) | 2017-11-08 | 2020-06-29 | Yuhua Li | Esters of dihydrotetrabenazine |
| WO2020086765A1 (en) | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| US12565495B2 (en) | 2019-08-12 | 2026-03-03 | Luye Innomind Pharma Shijiazhuang Co., Ltd. | VMAT2 inhibitor and preparation method therefor and application thereof |
| US20210087191A1 (en) | 2020-12-04 | 2021-03-25 | Dispersol Technologies, Llc | SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
-
2022
- 2022-03-21 AU AU2022241988A patent/AU2022241988A1/en active Pending
- 2022-03-21 FI FIEP22715479.6T patent/FI4168409T3/fi active
- 2022-03-21 PT PT227154796T patent/PT4168409T/pt unknown
- 2022-03-21 EP EP25172310.2A patent/EP4606429A3/en active Pending
- 2022-03-21 WO PCT/US2022/021080 patent/WO2022203984A1/en not_active Ceased
- 2022-03-21 KR KR1020237035676A patent/KR20230160308A/ko active Pending
- 2022-03-21 BR BR112023016273A patent/BR112023016273A2/pt unknown
- 2022-03-21 CN CN202280023462.8A patent/CN117062815A/zh active Pending
- 2022-03-21 HR HRP20250868TT patent/HRP20250868T1/hr unknown
- 2022-03-21 PL PL22715479.6T patent/PL4168409T3/pl unknown
- 2022-03-21 SI SI202230151T patent/SI4168409T1/sl unknown
- 2022-03-21 DK DK22715479.6T patent/DK4168409T3/da active
- 2022-03-21 MA MA60072A patent/MA60072B1/fr unknown
- 2022-03-21 EP EP22715479.6A patent/EP4168409B1/en active Active
- 2022-03-21 CA CA3207452A patent/CA3207452A1/en active Pending
- 2022-03-21 AR ARP220100663A patent/AR125188A1/es unknown
- 2022-03-21 ES ES22715479T patent/ES3032498T3/es active Active
- 2022-03-21 TW TW111110403A patent/TW202304901A/zh unknown
- 2022-03-21 IL IL305054A patent/IL305054A/en unknown
- 2022-03-21 CR CR20230448A patent/CR20230448A/es unknown
- 2022-03-21 MD MDE20230476T patent/MD4168409T2/ro unknown
- 2022-03-21 MX MX2023010566A patent/MX2023010566A/es unknown
- 2022-03-21 JP JP2023557361A patent/JP2024511053A/ja active Pending
- 2022-03-21 LT LTEPPCT/US2022/021080T patent/LT4168409T/lt unknown
- 2022-03-21 PE PE2023002681A patent/PE20240822A1/es unknown
- 2022-03-21 SM SM20250408T patent/SMT202500408T1/it unknown
- 2022-03-21 RS RS20250637A patent/RS67052B1/sr unknown
- 2022-03-21 HU HUE22715479A patent/HUE072220T2/hu unknown
-
2023
- 2023-01-12 US US18/096,073 patent/US11718618B2/en active Active
- 2023-06-09 US US18/207,807 patent/US20240010647A1/en active Granted
- 2023-09-04 JO JOJO/P/2023/0205A patent/JOP20230205A1/ar unknown
- 2023-09-18 EC ECSENADI202370370A patent/ECSP23070370A/es unknown
- 2023-09-18 DO DO2023000197A patent/DOP2023000197A/es unknown
- 2023-09-18 CO CONC2023/0012322A patent/CO2023012322A2/es unknown
- 2023-09-20 CL CL2023002785A patent/CL2023002785A1/es unknown
-
2025
- 2025-04-18 US US19/182,823 patent/US20250333413A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12421193B2 (en) | GPR52 modulators and methods of use | |
| AU2013291617B2 (en) | Carbamate/urea derivatives | |
| EP2968995B1 (en) | Inhibitors of lrrk2 kinase activity | |
| US20250333413A1 (en) | SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS | |
| JP2025531352A (ja) | ヘキサヒドロ－２ｈ－ピリド［２，１－ａ］イソキノリンｖｍａｔ２阻害剤および使用の方法 | |
| TW202432543A (zh) | 作為gpr52調節劑之化合物及組合物 | |
| WO2024091541A1 (en) | Compounds and compositions as gpr52 modulators | |
| EP3810595A1 (en) | Oga inhibitor compounds | |
| KR20240042472A (ko) | 무스카린성 수용체 4 길항제 및 사용 방법 | |
| EA050816B1 (ru) | Ингибторы vmat2 и способы применения | |
| HK40092922A (en) | Vmat2 inhibitors and methods of use | |
| HK40092922B (en) | Vmat2 inhibitors and methods of use | |
| WO2025199234A1 (en) | Vmat2 inhibitors and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231018 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250320 Comment text: Request for Examination of Application |